Smart nursing cuts kidney damage risk in liver cancer patients

NCT ID NCT07681817

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests whether a personalized nursing program can prevent acute kidney injury (AKI) in people with liver cancer who undergo interventional therapy. Researchers first use a prediction model to classify patients into low, moderate, or high risk for AKI. Then, they provide targeted nursing care—like hydration support and medication management—based on each patient's risk level. The goal is to see if this proactive approach lowers AKI rates compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

risk-stratified proactive nursing intervention

What this could lead to

If successful, this approach could reduce kidney injury after liver cancer procedures and improve patient recovery.

What could go wrong

This is a single-center study with 200 participants, so results may not apply broadly. The intervention is behavioral, not a drug, so effects may be modest.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CANCER, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••